Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Allbirds to Neutral

Guggenheim Downgrades Allbirds to Neutral

Guggenheim analyst Robert Drbul downgrades Allbirds (NASDAQ:BIRD) from Buy to Neutral.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Guggenheim analyst Robert Drbul downgrades Allbirds (NASDAQ:BIRD) from Buy to Neutral.

Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry

By Benzinga Insights

January 22, 12:01 PM

In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors…

PFE

Morgan Stanley Maintains Overweight on Seagen, Lowers Price Target to $170

By Benzinga Newsdesk

January 24, 10:27 AM

Morgan Stanley analyst Matthew Harrison maintains Seagen (NASDAQ:SGEN) with a Overweight and lowers the price target from $171 to $170.

SGEN

Dynavax’s Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations

By Vandana Singh

August 25, 10:31 AM

Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).

DVAX

IMAX’s High Profile Film Releases In Q4 & 2023 Make This Analyst Remain Bullish

By Anusuya Lahiri

September 26, 2:52 PM

Rosenblatt analyst Steve Frankel reiterated a Buy and $25 price target on IMAX Corp (NYSE:IMAX). The analyst reaffirmed his bullish view citing high-profile…

IMAX

Guggenheim Downgrades Allbirds to Neutral

Related Posts

Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry

Morgan Stanley Maintains Overweight on Seagen, Lowers Price Target to $170

Dynavax’s Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations

IMAX’s High Profile Film Releases In Q4 & 2023 Make This Analyst Remain Bullish